Journal
CANCER DISCOVERY
Volume 8, Issue 6, Pages 676-678Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-18-0368
Keywords
-
Categories
Funding
- Mentored Clinical Scientist Research Career Development Award [K08CA204732]
- Yale SPORE in Lung Cancer [P50 CA196530]
Ask authors/readers for more resources
A patient with advanced lung adenocarcinoma harboring a CD74-NRG1 gene rearrangement, which promotes ERBB2-ERBB3 heterodimerization and activation of downstream signaling, had an exceptional therapeutic response to an experimental anti-ERBB3 antibody. This result illustrates how NRG1 rearrangements, which are observed at a low frequency in a variety of solid tumors, may represent tractable therapeutic targets. (c) 2018 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
